ONCY — ONCOLYTICS BIOTECH INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1129928 ·
Last close
$0.75
Market Cap
$89.52M
52W High
$1.18
52W Low
$0.73
ADV30
1,365,107
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,281,000 | -9,243,000 | 8,161,000 | 5,493,000 | 13,291,000 |
| Dec 2025 | 0 | — | -9,651,891 | -9,177,897 | 7,582,000 | 5,202,000 | 11,381,000 |
| Sep 2025 | 0 | — | -9,944,315 | -10,346,686 | 10,818,753 | 8,875,157 | 10,736,124 |
| Jun 2025 | 0 | — | -4,169,986 | -4,505,426 | 14,597,143 | 10,688,786 | 10,147,258 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,672,000
Investing CF
$-11,000
Financing CF
$17,551,000
CapEx
$-13,970
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-438,738,000
Inventory
—
Receivables
$961,000
ST Investments
—
EBIT TTM
$-33,047,191
Pretax Income TTM
$-33,192,965
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,725,000 | -28,759,000 | 7,582,000 | 11,381,000 | — | -20,112,000 |
| Dec 2024 | 0 | -25,542,000 | -22,794,000 | 13,421,000 | 10,123,000 | — | -19,883,000 |
| Dec 2023 | 0 | -25,471,883 | -20,919,644 | 29,262,777 | 8,485,602 | — | -21,444,294 |
| Dec 2022 | 0 | -19,837,902 | -18,298,703 | 27,508,105 | 7,981,138 | — | -17,208,223 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | $89.67M | $5.22 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $90.50M | $3.49 | — |
| ZOMDF | Zomedica Corp. | $88.20M | $0.09 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $86.99M | $0.77 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $92.89M | $1.54 | — |
News headlines (Yahoo Finance, 1h cache)
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
2026-07-20 13:00 · Yahoo
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial
2026-07-16 11:16 · Yahoo
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)
2026-07-13 14:13 · Yahoo
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
2026-07-13 13:00 · Yahoo
Sector Update: Healthcare Stocks Advance in Afternoon Trading
2026-06-16 17:29 · Yahoo
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics
2026-06-16 16:42 · Yahoo
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
2026-06-16 13:00 · Yahoo
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention
2026-06-04 06:11 · Yahoo
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
2026-06-02 13:00 · Yahoo
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
2026-06-01 15:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.